Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 12, Issue 5, 1994, Pages 960-969

  Piedbois, P ^b   Buyse, M ^a   Blijham, G ^b   Glimelius, B ^b   Herrmann, R ^b   Valone, F ^b   Carlson, R ^b   Machiavelli, M ^b   Delfino, C ^b   Abad, A ^b   Petrelli, N ^b  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; METHOTREXATE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0028219974     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.5.960     Document Type: Article

References (35)

1. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
2. Bertino JR, Sawicki WL, Linquist CA, et al: Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 37:327-328, 1977
3. Allegra CJ: Methotrexate and fluorouracil following tamoxifen and premarin in advanced breast cancer. Semin Oncol 10:23-28, 1983 (suppl 2)
4. Danenberg PV, Danenberg KD: Effect of 5,10 methylenetetrahydrofolate and the dissociation of 5-fluoro-2-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism. Biochemistry 17:4018-4024, 1978
5. Curt GA, Allegra CJ, Fine RL, et al: Antimetabolites, in Pinedo HM, Chabners BA (eds): Cancer Chemotherapy Annual, vol 6. Amsterdam, the Netherlands, Elsevier Science Publishers, 1984, pp 1-30
6. Sant ME, Lyons SD, Phillips L, et al: Antifolates induce inhibition of amido phosphoribosyltransferase in leukemia cells. J Biol Chem 267:11038-11045, 1992
7. Cadman E, Davis L, Heimer R: Enhanced 5-fluorouracil nucleotide formation following methotrexate: Biochemical explanation for drug synergism. Science 205:1135-1137, 1979
8. Cadman E, Heimer R, Benz C: The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 256:1695-1704, 1981
9. Benz C, Schoenberg M, Choti M, et al: Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. J Clin Invest 66:1162-1165, 1980
10. Herrmann R, Spehn J, Beyer JH, et al: Sequential methotrexate and 5-fluorouracil: Improved response rate in metastatic colorectal cancer. J Clin Oncol 2:591-594, 1984
11. Ignoffo RJ, Friedman MA, Gribble M, et al: Phase II study of sequential methotrexate and 5FU plus mitomycin and leucovorin in patients with disseminated large bowel cancer: Northern California Oncology Group Study. Cancer Treat Rep 68:983-988, 1984
12. Kemeny NE, Ahmed T, Michaelson RA, et al: Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: Attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate. J Clin Oncol 2:311-315, 1984
13. Leone BA, Romero A, Rabinovich MG, et al: Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma. J Clin Oncol 4:23-27, 1986
14. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 10:904-911, 1992
15. Blijham GH, Stellestags J, Sahmoud T, et al: The modulation of high-dose 5-fluorouracil with low-dose methotrexate in metastatic colorectal cancer: A phase III study of the EORTC GI Cancer Cooperative Group. Proc Am Soc Clin Oncol 12:586, 1993 (abstr)
16. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 7:1437-1446, 1989
17. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 10:1407-1418, 1989
18. Herrmann R, Knuth A, Kleeberg U, et al: Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Ann Oncol 3:539-543, 1992
19. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989
20. Machiavelli M, Leone BA, Romero A, et al: Advanced colorectal carcinoma: A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. Am J Clin Oncol 14:211-217, 1991
21. Delfino C, Caccia G, Maniago O: 5-Fluorouracil alone versus methotrexate + leucovorin + FU in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:521, 1992 (abstr)
22. Abad A, Garcia P, Gravalos C, et al: Phase III trial with methotrexate, 5-FU and high-dose leucovorin vs. 5-FU, leucovorin vs. 5-FU in advanced and metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:459, 1992 (abstr)
23. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
24. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
25. Buyse M, Piedbois P: Meta-analyses: Use and misuse. J Clin Oncol 11:382, 1993 (letter)
26. Piedbois P, Buyse M: What can we learn from a meta-analysis of trials testing the modulation of 5-fluorouracil by leucovorin? Ann Oncol 4:S15-S19, 1993
27. Mantel H, Haenzel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
28. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient (II. Analysis and examples). Br J Cancer 35:1-39, 1977
29. Cox DR: The Analysis of Binary Data. London, England, Methuen, 1970
30. Cox DR: Regression models and life tables (with discussion). J R Stat Soc (B)34:187-220, 1972
31. Glimelius B: Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 4:235-240, 1993
32. Mini E, Bertino JR: Time and dose relationships for methotrexate, fluorouracil and combinations of these drugs for maximum cell kill in human CCRF-CEM cells. Proc Am Assoc Cancer Res 23:181, 1982 (abstr)
33. Marsh JC, Bertino JR, Katz KH, et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9:371-380, 1991
34. Abad A, Rosell R, Pastor MC, et al: Sequential combination of methotrexate, 5-fluorouracil, and high-dose folinic acid in advanced colorectal cancer: Double biochemical modulation? Am J Clin Oncol 14:393-396, 1991
35. Romanini A, Bertino JR: Leucovorin effects on sequential methotrexate or trimetrexate-5-fluorouracil cytotoxicity. Proc Am Assoc Cancer Res 31:389, 1990 (abstr)